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Introduction
CTCF is an 11 zinc finger protein factor involved in cellular activities 
which include gene expression regulation, cellular architectural 
organization, long range chromatin interactions, insulation and 
genomic imprinting [1,2]. These varied activities are mediated with 
multiple combinations of its 11 zinc fingers with subsequent phenotype 
possibly determined by protein partners [3] and post translational 
modifications [4,5]. Dysregulation of these processes could lead to 
cellular transformation. Indeed a fast running CTCF isoform was 
specifically found expressed in breast cancer tissue but not in normal 
breast tissue and lower expression level of this isoform was associated 
with worse prognostic indices [6].
 Initial evidence supporting the role of estrogen in breast cancer was 
found in MCF 10A and MCF 10F cells which are immortalized estrogen 
- and progesterone - receptor negative, breast epithelial cell lines [7,8]. 
These cells were transformed on estrogen stimulation as evidenced by 
the acquisition of anchorage-independent growth, loss of their usual 
duct pattern, invasiveness on Matrigel and induction of palpable tumors 
in severe combined immune-deficient (SCID) mice [7,8]. Though the 
fore mentioned studies observed the transforming effect of estrogen, 
they did not comment on how estrogen gained entry seeing that the 
cells were estrogen receptor (ER) negative. The ER expression status of 
a cell is defined by nuclear immunohistochemical staining but it is now 
clear that ER is also expressed on the cell membrane as well as in the cell 
cytoplasm [9-11]. Those cells typically classified as ER negative could 
also possess ER on the cell membranes as well as the cytoplasm and 
this might explain how estrogen gained entry into ER negative cells. 
More recent evidence linking estrogen and breast cancer was provided 
in a prospective case - control study which assessed the link with liquid 
chromatography/tandem mass spectrometry [12]. This study found a 
statistically significant association between unconjugated estradiol, 
high methylation levels of the 4-hydroxylation product of estradiol 
and increased breast cancer risk in a cohort of 277 postmenopausal 
patients. Taken together, estrogen therefore possessed a direct breast 
cell mitogenic effect and was also a precursor to a potent mutagen - 
namely excessively methylated 4-hydroxylation products [12,13]. 
An accumulating body of evidence has pointed to a relationship 
between CTCF and ERα in breast cancer. This body of evidence 
indicates that first, exogenous estrogen (E2) down regulated CTCF 
mRNA expression in the ER+ MCF7 cells, an effect that was greater 
at higher estrogen concentrations [14]. Furthermore, the CTCF 
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Abstract
Introduction: CTCF is an evolutionally conserved 11-zinc finger protein factor involved in an array of processes 
whose deregulation could lead to cellular transformation. Through interactions with ERα binding regions and ER-
regulated genes, CTCF was shown to compartmentalize the cellular genome into domains. It also colocalized with 
ERα in MCF7 cells and had interactions with ERα during histone deacetylase recruitment and fork-head activity. A 
fast-running isoform was previously shown to be expressed in breast cancer tissue but not in normal breast tissue. 
It is not clear whether there is a regulatory relationship between CTCF and ERα in breast cancer.
Aim: To determine whether CTCF expression regulated ERα expression in the ER+ MCF7 breast cancer cell 
line. 
Methods: MCF7 breast cancer cells were transfected with either CTCF expression vectors or siRNA against 
CTCF. Following CTCF over-expression and knock-down, changes in endogenous expression of ERα gene and 
protein expression were monitored by quantitative polymerase chain reaction (using MIQE guidelines) and western 
blot analysis respectively. 
Results: CTCF plasmid overexpression and siRNA knockdown was associated with cell rounding but with 
96.4% and 95.7% cell viability respectively. Increase in CTCF mRNA on over-expression was associated with a rise 
in CTCF protein expression. siRNA knockdown of CTCF mRNA was accompanied by a corresponding decrease 
in CTCF protein expression. CTCF over-expression and knockdown appeared to inhibit the ability to detect ERα 
protein expression by western blotting. Neither the over-expression nor knockdown of CTCF altered ERα mRNA 
expression as detected by QPCR.
Conclusion: Alterations in CTCF mRNA expression did not affect ERα gene expression in MCF7 cells 
suggesting that CTCF interactions with the estrogen receptor in breast cancer may not be mediated via direct 
regulation of ERα mRNA expression.
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lysate sample to be tested was placed at the bottom of the 10th and 11th 
wells also in duplicate. One part of the dye reagent concentrate (Bio-
Rad, USA) was diluted with 4 parts of deiodised water (Bio-Rad, USA) 
and 200 µl of the solution pipetted to each of the 11 wells in duplicate 
and mixed gently. The plate was allowed to stand at room temperature 
for 30 minutes and placed in a spectrophotometer (BioRad, USA) with 
absorbance measured at 595 nm. A graph plotting absorbance versus 
BSA standard concentrations was created and a best fit line drawn to 
determine protein concentrations.
RNA extraction 
To lyse and release RNA from incubated cells, 1 ml of TRIsure 
(Bioline, UK) was placed into each well of a 12 well plate and incubated 
at room temperature for 5 minutes with gentle rocking and pipetting. 
In order to separate the three different phases into which lysed cells 
partition, 0.2 ml of chloroform was added and solution shaken 
vigorously by hand for 15 seconds and incubated at room temperature 
for 3 minutes. Centrifugation at 12000x g (Eppendorf centrifuge 5415 
R, Germany) for 15 minutes at 4°C was subsequently performed and 
the colourless upper aqueous phase (containing RNA) taken, mixed 
with 0.5 ml ice cold isopropanol and incubated at room temperature 
for 10 minutes. It was centrifuged at 12000x g (Eppendorf centrifuge 
5415 R, Germany) for 15 minutes at 4°C to precipitate RNA. The 
supernatant was removed and pellet washed in 1ml of 75% ethanol by 
inverting. Further centrifugation at 7500x g for 5 minutes at 4°C was 
done and the pellet allowed to air dry for at least 10 minutes. It was then 
dissolved in 45 µl of RNAse free water (Fisher, USA) and incubated for 
10 minutes at 55°C. To remove contaminating DNA, 5 µl of 10x Turbo 
DNAse buffer (1x final) (Ambion, USA) and 1 µl of Turbo DNAse (2 U/
µl) (Ambion, USA) were added and solution incubated at 37°C for 30 
minutes. 0.1 (10%) volume DNAse inactivation agent (Ambion, USA) 
was added, solution incubated for 2 minutes at room temperature (RT) 
and centrifuged at 10,000x g (Eppendorf centrifuge 5415 R, Germany) 
for 2 minutes at 4°C. The supernatant was frozen at -20°C. 
NA quality assessment using the AGILENT 6000 bioanalyser 
1 μl of RNA 6000 Nano dye concentrate was added to 65 μl aliquot 
of filtered RNA 600 Nano gel, vortexed thoroughly and centrifuged for 
10 minutes at 13000x g while protecting it from light. The RNA Nano 
chip was placed on the chip priming station and 9 μl of the gel-dye 
mix pipetted at the bottom of the well-marked ‘G’. Using the plunger 
on the priming station the gel was dispersed across the chip. A further 
9 μl of the gel-dye mix was pipetted to the bottom of two other marked 
wells. 5 μl of the RNA 6000 Nano marker was subsequently pipetted 
to the bottom of the well-marked with a ladder symbol and into 
each of the 12 sample wells (numbered 1-12). 1 μl of the RNA ladder 
was pipetted to the well-marked with the ladder symbol and 1 μl of 
RNA samples was placed in each sample well. The chip was vortexed 
(Vortexer, Agilent, Germany) for 60 seconds at 2400 rpm (vortex “set 
point”) and immediately inserted into the Bioanalyzer 2100 and run 
with “Eukaryotic RNA nano series II” program. 
Bacterial cell transformation using DH5αTM competent cells 
For each transformation reaction, 50 µl of DH5αTM cells was mixed 
with 1 ng - 10 ng (1 µl - 5 µl) of plasmid DNA and placed on ice for 
30 minutes. It was heated at 42°C for 20 seconds without shaking and 
placed on ice for 2 minutes. 950 µl of pre-warmed luria broth was added 
to the bacterial cell/DNA mix and incubated at 37°C with shaking at 225 
rpm for one hour. Two different volumes of the transformation reaction 
were collected and spread on two separate agar plates (prepared with 
promoter was found to harbor the estrogen response element (ERE) 
consensus sequence suggesting that the CTCF promoter could be a 
target for ERα [14]. Estrogen stimulation also recruited CTCF to the 
CDKN1c promoter leading to epigenetic silencing of that promoter 
possibly via methylation [15]. Second, investigation using ChIP - Seq 
showed that estrogen - down regulated gene regions were more likely 
to be co-bound by CTCF and ER than by either alone in MCF7 cells. 
Also CTCF and ER binding events were found to colocalise and there 
was significant ERE and CTCF motif enrichment in those colocalised 
regions. Despite evidence for colocalisation, we did not demonstrate 
physical binding between CTCF and ERα on mass spectrometry in 
MCF7 cells (manuscript in preparation). Third, Ross-Innes, et al. 
[16] discovered that CTCF compartmentalized the genome in MCF7 
cells into domains that contained ERα binding regions and ER-
regulated genes. Fourth, the fork head protein (FOXA1/HNF3α) which 
modulates ERα - chromatin interactions and is an absolute requirement 
for ERα binding to ER promoters (even in the absence of E2 binding) is 
itself negatively regulated by CTCF [17]. Fifth and finally, both CTCF 
and ERα recruited histone de-acetylase (HDAC) which via histone de-
acetylation repressed gene expression [18,19].
Taken together, these pieces of evidence suggested a link between 
CTCF and ERα but the exact nature of that connection is not clear. 
Seeing that recent evidence suggested that CTCF and ERα colocalised 
but were not physically bound (manuscript in preparation) this paper 
therefore investigated a possible direct regulatory effect of CTCF on 
ERα expression in the ER positive MCF7 breast cancer cell line.
Materials and Methods
Breast cancer cell (BCC) lines and cell culture 
MCF7 (ER+/PR+, HER2-) cells were cultured in DMEM/Ham’s 
F12 medium (Life Technologies, UK). Cells were passaged when 
they reached 70% - 80% and cell work was performed as described in 
Docquier, et al. [6]. Cells were obtained from the European cell bank 
and were used up within 6 months of purchase. 
Cell lysate for western blot analysis 
20 µl of 2x lysis/loading buffer was mixed with 1 × 105 cells and 
the solution immediately vortexed (Whitimixer TM, Fisherbrand) to re-
suspend the cell pellet. Heating at 95°C with a heating block (TECHNE, 
USA) for 5 minutes was done and lysates were used immediately or 
frozen at -20°C for use at a later date.
Trypan blue test for cell viability 
Cell suspension was prepared as described in Docquier, et al. [6]. 
200 µl of this suspension was placed in an Eppendorf tube containing 
500 µl of 0.4% trypan blue solution (Sigma, UK) and 300 µl of 
Hanks’ Balanced salt solution (GIBCO, UK). The solution was mixed 
thoroughly and allowed to stand for 10 minutes at room temperature. 
10 µl of the solution was introduced into a counting chamber and cells 
counted using a haemocytometer (Neubauer chamber - Marienfeld TM, 
Germany). 
Bovine serum albumin protein assay 
BSA (Sigma, USA) standards were thawed at room temperature and 
10 µl of each pipetted at the bottom of 7 wells of a labelled 96 well micro 
titre plate (BioRad, USA) in duplicate. A further 10 µl of distilled water 
and an equal volume of the buffer used to prepare lysates were pippetted 
to the bottom of the 8th and 9th wells in duplicate to serve as negative 
controls. Furthermore, 10 µl each of a 1:1 and 1:2 dilution of the cell 
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the appropriate antibiotic) and left to dry in a hood for 20 minutes. The 
agar plates - wrapped to prevent desiccation - were incubated at 37°C 
overnight. 
Preparation of bacterial culture 
To make bacterial broth, 5 ml Luria broth (and 5 µl of appropriate 
antibiotic: 100 µg/µl for both kanamycin and ampicillin) was placed in 
a 10 ml GrainerR tube. A single colony of bacterial cells growing on an 
agar plate was picked with a sterile yellow tip and the tip placed in the 
Grainer tube. This tube was then incubated with shaking (225 rpm) 
(MaxQ, ThermoScientific, USA) overnight at 37°C. Bacterial growth 
was evidenced by a cloudy medium.
DNA quantitation with ultraviolet (UV) spectrophotometry 
(Nanodrop) 
The spectrophotometer was first blanked with 1.5 µl of RNAse free 
water then 1.5 µl of each sample was placed on the cuvette and DNA 
concentration read off. Another blanking was done to clean out the 
cuvette.
Plasmid restriction enzyme digestion and agarose gel 
electrophoresis 
Agarose (1%) solution was prepared in TAE buffer, poured into 
a gel casting tray (ThermoFisher, USA) with combs already inserted 
and allowed to stand for 30 minutes. The tray was transferred to a 
horizontal electrophoresis tank (ThermoFisher, USA) and covered with 
TAE buffer solution. Samples (including loading buffer) already treated 
with digestion enzymes and SYBR green were loaded into the wells and 
electric field of 100 V applied in the dark for one hour. Nucleic acid 
bands post electrophoresis were visualised with the Odyssey infrared 
scanner (Licor, UK).
Plasmid extraction using the endofree plasmid Maxiprep kit 
(QIAGEN TM) 
Large scale (maxi) preparation of plasmids was performed with the 
endofree plasmid maxi kit (Qiagen TM) after confirming the plasmids 
via minipreparation, enzyme digest and gel electrophoresis, according 
to the manufacturer’s recommendation.
Transfection assays with plasmid expression vectors 
Incubated cells on achieving 40% - 80% single layer confluence 
were trypsinised and counted. An appropriate density of cells was 
diluted in antibiotic-rich medium and placed into each well of a 12 
well plate. The cells were incubated with 5% CO2 overnight at 37°C. 
Transfection was performed on achieving 40% to 70% cell confluence. 
To prepare the transfection complexes, plasmid vector and transfection 
reagent (Attractene, Qiagen) suspensions were prepared individually 
using antibiotic - free medium and left to stand for 5 minutes at RT. The 
plasmid solution was mixed with attractene transfection reagent and 
incubated for a further 20 minutes at RT. Complete medium was added 
to make a final volume of 1000 µl for each well of a 12 well plate. Culture 
medium from the incubated cells was removed and 1000 µl of prepared 
transfection complexes placed in each well. The cells were incubated 
with 5% CO2 at 37°C for a total of 48 h and transfection complexes 
removed and replaced with fresh medium after 12 hours of incubation. 
Transfection assays with small interfering RNA (siRNA) 
To prepare transfection complexes, siRNA (Dharmacon, 
ThermoScientific) and transfection reagent (DharmaFECT 1, 
ThermoScientific) suspensions were prepared individually using serum 
- and antibiotic - free media and left to stand for 5 minutes at RT. siRNA 
dilution was mixed with the transfection reagent and incubated for 
20 minutes at RT. Antibiotic-free medium was added to make a final 
volume of 1000 µl for each well of a 12 well plate. Culture medium from 
the incubated cells was removed and 1000 µl of prepared transfection 
complexes placed in each well. The cells were incubated with 5% CO2 
at 37°C for a total of 48 h - 72 h and transfection complexes removed 
and replaced with fresh medium (antibiotic-free) after 12 hours of 
incubation. At the end of incubation, transfected cells were lysed for 
RNA extraction and QPCR or prepared for SDS-PAGE and subsequent 
western blotting. 
Sodium dodecyl sulphate (SDS) - poly acrylamide gel 
electrophoresis (PAGE) and western blot analysis 
Resolving buffer (6% - 8%) was poured between glass plates of the 
electrophoresis equipment (ThermoFisher, USA) and left to polymerise 
for 15 minutes. Stacking buffer was poured after inserting a 9 - well 
comb and left to stand for another 15 min. Combs were removed 
and wells (covered with running buffer) washed and loaded with 
lysates. Electrophoresis was performed at 125 volts - 40 milliAmperes 
(mA) - 5 watts for two hours. Proteins were transferred from gels 
to polyvinylidene fluoride (PVDF) membrane (Millipore, USA) at 
100 mA - 35 volts for 2 hours. The membrane was blocked with 3% 
non-fat fresh milk (Marvel) for 2 hours and incubated with primary 
antibody overnight at 4°C. Further incubation with secondary antibody 
- horseradish peroxidase (HRP) labelled was performed for 2 hours at 
room temperature with shaking. The signal was detected using the ECL 
method. 
Stripping blot membranes 
Primary and secondary antibodies in blotted membranes were 
removed by placing the membrane in 100 ml of warm (55°C) strip 
buffer composite solution (4 g SDS, 1.4 ml β-mercaptoethanol, 1.51 g 
TRIS in 200 ml distilled water) and rocked every 5-10 minutes. The 
membrane was washed for 10 minutes with PBS-T (pH 7.5) and the 
incubation and wash steps repeated one more time. 
Complimentary DNA (cDNA) synthesis 
1 µg of RNA was denatured by heating at 70°C for 5 minutes and 
placed immediately on ice. It was mixed with 4 µl of 5x cDNA synthesis 
buffers, 2 µl of 500 µM dNTP mix, 1 µl of anchored oligodT primers 
(500 ng/µl), 1 µl of 0.5 µM Verso enzyme mix and 1 µl of reverse 
transcriptase enhancer, all from the Verso cDNA kit (ThermoScientific, 
UK). The reaction mixture was made up to 20 µl with RNAse free water 
and incubated in a PCR machine (Genestorm, England) at settings 
consistent with the manufacturer’s instructions. The cDNA sample was 
saved at -20°C for subsequent applications.
Preparing primers for quantitative PCR (QPCR) 
To prepare 100 µM solution of primer pair, the vial containing the 
dry primer powder was spun down and the recommended amount of 
RNAse free water (from technical sheet) was placed in the tube and 
mixed by inverting several times. The tube was kept on ice for 20 
minutes, centrifuged again and stored at -20°C.
Standard curve determination for QPCR efficiency 
A serial log dilution of cDNA for QPCR was obtained from neat to 1 
× 104 concentrations. QPCR was then performed as with the procedure 
below. A standard curve was automatically generated by the thermal 
cycler (CFX Connect TM, Bio-Rad, USA).
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Quantitative polymerase chain reaction (QPCR) 
Two wells (duplicate) of a 96 well plate were loaded with 5 µl of a 
solution containing 5 µl of Kapa mastermix, 3 µl of diluted (1:5) cDNA, 
3 µl of RNAse - free water and 1 µl of 10 µM concentration of the 
relevant primer. The plate was centrifuged for one minute and loaded 
into the thermal cycler (CFX Connect TM, Biorad, USA). The settings for 
the thermal cycler corresponded to the manufacturer’s instructions for 
optimum temperatures for the Kapa mastermix. 
Results
CTCF plasmid DNA overexpression and siRNA knockdown 
optimisation 
To investigate the effect of CTCF on ERα expression we first 
determined the optimum conditions for CTCF plasmid DNA 
overexpression transfection assays by using varying amounts of plasmid 
DNA and attractene transfection reagent in 2.0 × 104 cells/ml of MCF7 
cells. Lysates were prepared and proteins separated by SDS PAGE and 
blotted membranes probed serially with anti-CTCF (BD Biosciences, 
0.5 µg/ml dilution), anti-ER (MA 310, ThermoScientific, 5 µg/ml), anti-
ER (Abcam 2647, 1 µg/ml) and mouse monoclonal anti-actin (1:2000 
dilution) antibodies. As shown in Figure 1A, ~80% CTCF protein 
overexpression was obtained compared to the empty vector plasmid 
using 1.2 µg of plasmid DNA and 3 µl of attractene. Shown also are 
extra protein bands at ~120 kDa in the lanes with overexpressed CTCF 
which could suggest that the extra CTCF protein produced by the cell 
on CTCF overexpression included isoforms with different molecular 
weights. No ERα expression was detected by western blotting however at 
any of the CTCF transfection conditions despite using up to three times 
the manufacturer’s recommended anti-ERα antibody concentrations 
and with upwards of of cell lysate. This lack of visualisation was evident 
for both CTCF plasmid and empty vector control samples but not for 
untreated MCF7 whole cell lysates. 
 Similar experiments were performed to determine optimum CTCF 
siRNA knockdown conditions. 100 pmol and 250 pmol respectively of 
CTCF siRNA and negative control non target siRNA were transfected 
with 2.66 µl of DharmaFECT 1 transfection reagent for each well of a 
12 well plate. As shown in Figure 1B, there was about 90% knockdown 
of CTCF protein expression with CTCF siRNA compared to the non-
target siRNA and untreated MCF7 cells. As with the overexpression 
experiments, no protein bands were visualised on probing with anti-
ERα antibodies for both siRNA and non-target control samples. 
 As ERα protein expression could not be determined by western 
blotting after cell transfection, further experiments studying gene 
expression were performed to determine whether CTCF overexpression/
knockdown had an effect on ERα gene expression. The combination of 
1.2 µg plasmid DNA, 3 µl attractene transfection reagent and 2.0 × 104 
cells/ml MCF7 cell density in a single well of a 12 well plate, incubated 
for 48 hours; and 250 pmol of CTCF siRNA, 2.66 µl of DharmaFECT 1 
transfection reagent, and 1.33 × 105 MCF7 cell density in a single well 
of a 12 well plate, incubated for 72 hours, served as optimal conditions 
for CTCF transfection experiments.
Effect of transfection agents and reagents on MCF7 cell 
growth and viability
To determine the response of MCF7 cells to transfection reagents 
and confirm that cells were still viable after transfection, MCF7 cells 
were incubated with transfection reagents as shown in Figure 2. The 
concentrations and volumes of reagents used matched those used to 
achieve overexpression and knockdown in Figure 1A and 1B. Cell death 
manifested by cell rounding and loss of confluence was observed in cell 
panels incubated with CTCF pCI, EV pCI and CTCF siRNA. Ectopic 
expression of CTCF had previously been shown to profoundly inhibit 
cell growth with and without apoptosis [20,21]. It is however not clear 
why there was cell death with the EV pCI. Since CTCF expression was 
associated with cell survival it is not surprising that CTCF knockdown 
was associated with cell death. Using the trypan blue cell viability assay 
there was a 96.4% and 95.7% viability detected for MCF7 cells after 
48 h (overexpression) and 72 h (knockdown) transfection incubation 
respectively (not shown). These numbers suggested that MCF7 cells 
remained viable post transfection allowing for further downstream 
processes.
QPCR optimisation assays 
In order to further assess the effect of CTCF on ERα, gene expression 
studies were performed using QPCR following transfection of MCF7 
cells with plasmid expression vectors and siRNA. On account of 
reproducibility issues associated with some QPCR data published in the 
literature, the Minimum Information for Publication of Quantitative 
Real-Time PCR Experiments (MIQE) guidelines [22] were used to 
determine the interplay between CTCF and ERα in this paper and 
included assessing RNA quality, primer structure and QPCR efficiency.
Figure 1: (A) Optimisation of MCF7 overexpression with a plasmid 
expression vector. The effect of different amounts plasmid DNA (CTCF tagged 
and empty vector) and transfection reagent on CTCF protein expression is 
shown. Shown is about 80% CTCF protein overexpression using 1.2 μg of DNA 
and 3 μl of attractene transfection reagent compared to 1.2 μg of the empty 
vector (EV) pCI. (B)  MCF7 cell RNA interference (RNAi) with CTCF and 
non-target siRNA. MCF7 cells treated with 100 pmol and 250 pmol of CTCF 
and nontarget siRNA using 2.66 µl of DharmaFECT1 as transfection reagent 
and incubated for 72 h. About 90% CTCF protein knockdown demonstrated 
with both siRNA concentrations. 
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Bioanalyser and Nanodrop estimation of RNA quality and 
concentrations 
Results in Figure S1a (supplementary file) show the quality of RNA 
samples used for QPCR in this paper and indicate two clear bands that 
represent the 18S and 28S ribosomal proteins in the densitometry plot. 
There were no extra bands suggesting the absence of contaminating 
nucleic acids in the samples. Further confirmation of RNA quality is 
shown in Figure S1b (supplementary file) which are spherograms 
generated by the bioanalayser by plotting the intensity of fluorescence 
with size/migration time of RNA in each sample. It confirmed the 
absence of nucleic acid contaminants by showing only two peaks which 
represent 18S and 28S RNA in all the samples. The bioanalyser was also 
used to estimate the RNA integrity number (RIN) and a number of 8 
and over is taken as good RNA quality with a value of 10 the highest 
possible quality [23]. Table S1 (supplementary file) showed that the 
lowest RIN in the extracted RNA samples was 9.4 in the knockdown 
sample with CTCF siRNA. This result suggested that RNA used for 
the QPCR experiments was of pure quality with no contamination or 
degradation. This conclusion was further confirmed by the 260/280 
absorbance ratio determined by the Nanodrop spectrometer where 
the lowest absorbance ratio was 1.93 in the sample with EV pCI. A 
reading of between 1.8 and 2.0 is considered pure nucleic acid material 
[24]. Finally, RNA concentrations were estimated using the Nanodrop 
spectrometer and are also listed (supplementary file).
DINAmeltR prediction of secondary structures of primer 
pairs for QPCR 
Proper primer annealing is required for reliable QPCR and 
exaggerated primer secondary structures could interfere with this 
process. The DINAmelt software was used to assess the extent of 
secondary structures of the primers used in this paper. Forward and 
reverse sequences of all primers used for QPCR were entered into the 
Two-state melting (folding) section of the DINAmelt software and 
assessed at temperature=55°C, magnesium=5 nH, sodium (Na)=50 nH 
for RNA folding pattern [25]. As shown in Figure 6 (supplementary 
file), none of the primers possessed an exaggerated secondary structure 
predicting that there would be minimal primer interference.
Standard curves and melting curves 
A linear standard curve with an amplification efficiency of 90% 
- 100%, slope of -3.9 to -3.0 and R^2 value > 0.98 (all influenced by 
replicate consistency) and single peak melting curves [22] combine to 
determine a fully validated QPCR assay. The result in Figure 3 showed 
that the standard curve for the CTCF primer pair (A) was linear and 
demonstrated a slope of -3.369, R^2 of 0.986 and efficiency of 98.1%. 
The ERα primer pair (B) demonstrated a slope of -3.406, R^2 of 0.996 
and efficiency of 96.6%; GAPDH primer pair (C) had a slope of -3.343, 
R^2 of 0.996 and an efficiency of 95.5%; and TBP primer pair (D) 
showed a slope of -3.367, R^2 of 0.987 and efficiency of 98.2%. These 
values were within expected limits for an accurately optimized QPCR 
Figure 2: MCF7 cell response to expression vectors and attractene transfection 
reagent. Shown are MCF7 cells transfected with 1.2 µg of CTCF pCi plus 3 µl 
attractene (A), 1.2 µg of EV pCi plus 3 µl attractene (B), 3 µl attractene alone 
(C) and no treatment (D) in the overexpression assays panels. Also MCF7 
cells transfected with 250 pmol of CTCF siRNA using 2.66 µl DharmaFECT 
1 (A); 250 pmol of non-target siRNA using 2.66 µl DharmaFECT 1 (B); 2.66 µl 
DharmaFECT 1 only (C); and no treatment (D) in the knockdown assays panels. 
The panels show the extent of cell confluence and cell rounding (indicating cell 
death) on treatment and show some cell loss in cells transfected with plasmid 
expression vectors and CTCF siRNA.
Figure 3: Standard curves for QPCR efficiency. MCF7 cDNA was reverse 
transcribed from 1 µg of RNA and serially diluted 10 fold from neat to 1:10, 
1:100 and 1:1000. Samples were amplified by QPCR with (A) CTCF, (B) ERα 
(C) GAPDH and (D) TBP primer pairs using Kapa mastermix. The reaction 
efficiency, slope and R^2 values for each primer is indicated in the box for each 
graph. The values were within expected ranges for an accurately optimised 
QPCR assay.
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assay. Furthermore, Figure 4 revealed single melt peaks confirming the 
presence of a specific nucleic acid product from a specific primer pair 
and that there was no contamination with other nucleic acid material.
Variation in CTCF mRNA expression and ERα gene expression 
response in MCF7 breast cancer cells 
Using the CTCF overexpression and knockdown conditions 
previously achieved, QPCR was performed to determine whether 
variation in CTCF mRNA affected the expression of ERα mRNA. The 
results in Table 1, achieved with QPCR conditions well within standard 
efficiencies as shown in the previous section, confirmed that CTCF 
overexpression ΔCq of 4.01 (fold change of 16.11) was associated 
with a ΔCq of -0.72 (fold change of 1.65) in ERα mRNA expression. 
Furthermore, CTCF knockdown ΔCq of -2.11 (fold change of 4.32) 
was associated with just ΔCq of 0.17 (1.13 fold change) in ERα mRNA 
expression. The expression of reference genes GAPDH and TBP 
remained constant for both test material and controls in each set of 
experiments which indicated that the change(s) identified in CTCF and 
ERα expression were not due to variations in the general expression of 
RNA in the cells. 
Discussion
The previous section revealed results we obtained while 
interrogating a possible regulatory impact of CTCF on ERα expression. 
MIQE guidelines were adhered to and we showed that RNA quality, 
primer secondary structure, reaction efficiency and primer melting 
points were all optimal for QPCR. The results revealed that MCF7 
cells suffered some degree of cell death when subjected to transfection 
reagents. However, cell viability was sufficient for downstream 
processes. Also, an increase in CTCF mRNA expression occurred 
with a corresponding rise in CTCF protein expression and vice versa. 
Furthermore, transfection processes appeared to inhibit the ability 
to detect ERα protein expression in MCF7 cells. The results obtained 
however indicated that there was no direct regulatory effect of CTCF 
mRNA expression on ERα gene expression as neither a 16.11-fold 
overexpression of CTCF mRNA nor a 4.32-fold knockdown of CTCF 
mRNA had any discernible effect on ERα mRNA expression levels in 
MCF7 cells. 
 One main surprise in this paper was the inability to detect ERα 
protein expression in transfected MCF7 cells by western blotting though 
that expression had been detected in untreated whole cell lysates. Using 
augmented amounts of anti ERα antibody and different quantities of cell 
lysate did not make any difference. The reason for this finding is obscure 
and implicating antibody quality would not be justified as the anti ERα 
antibodies detected their associated protein in MCF7 whole cell lysates. 
There is evidence however suggesting that transfection processes could 
lead to unexpected abnormalities in cells which could include epitope 
masking. Evidence for this was suggested by Reynard, et al. [26] who 
studied the effect of a transfected membrane-bound glycoprotein 
(GP) in human embryonic kidney 293 (HEK293T) cells. The authors 
noted that while transfection of pCMLTrkA-GFP alone lead to a rise 
in TrkA and GFP on flow cytometry, cotransfection of phCMVGP and 
pCMLTrkA-GFP however gave rise to cells which while overexpressing 
Figure 4: Assessment of QPCR replicate consistency and melting curves. 
MCF7 cDNA (reverse transcribed from 1 µg of RNA) at 1:5 dilution was amplified 
in duplicates by QPCR using CTCF, estrogen receptor (ER) α, TATA box protein 
(TBP) and GAPDH primer pairs respectively. The amplification curve indicating 
replicate consistency for each primer pair is shown. Also shown is the single 
peak melting point for each primer pair indicating the absence of nucleic acid 
contamination?
Table 1: ERα mRNA fold change on CTCF overexpression and siRNA 
knockdown CTCF was overexpressed in MCF7 cells with a CTCF expression 
vector (CTCF pCI) and control empty vector (EV) pCI (A) and underwent knockdown 
on transfection with CTCF siRNA and a control EV siRNA (B). cDNA was reverse 
transcribed from 1 µg of extracted RNA and subjected to QPCR. Values are the 
average of two experiments, performed in duplicate. Table shows Cq levels for 
mRNA expression and fold changes for CTCF overexpression (A) and CTCF 
knockdown (B). Also shown are Cq levels for mRNA expression and fold changes 
for ERα and for reference genes GAPDH and TBP. A Cq change of less than 0.8 
is accepted as ‘no difference’ in gene expression levels. The result indicates no 
significant change in ERα mRNA expression with significant fold changes in CTCF 
mRNA expression.
Cq ± SD
CTCF pCI
Cq ± SD
EV pCI
Cq change Fold change
CTCF 17.005 ± 0.0495 21.015 ± 0.0353 4.01 16.11
ERα 21.5 ± 0.071 20.78 ± 0.0283 -0.72 1.65
GAPDH 17.425 ± 0.106 17.175 ± 0.064 -0.25
TBP 23.34 ± 0.14 22.745 ± 0.191 -0.59
(A)
Cq ± SD
CTCF siRNA
Cq ± SD
Non target siRNA
Cq change Fold 
change
CTCF 24.06 ± 0.014 21.945 ± 0.078 -2.11 4.32
ERα 20.835 ± 0.219 21.005 ± 0.007 0.17 1.13
GAPDH 18.45 ± 0.1697 18.52 ± 0.0567 0.07
TBP 23.68 ± 0.106 23.455 ± 0.0778 -0.22
(B)
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GP and showing abundant GFP, revealed little TrkA expression. Using 
confocal microscopy, the authors found that cells overexpressing GP 
revealed very low TrkA surface staining though high levels of TrkA-
GFP remained evident. They concluded therefore that overexpressed 
GP most likely masked the TrkA epitope and prevented its recognition 
by its antibody. The same could be adduced for the results in this paper 
though it wouldn’t explain why CTCF knockdown should have a 
similar effect.
Another issue of note is the apparent discrepancy between the 
extent of CTCF mRNA fold change and the associated CTCF protein 
change. As seen in Figure 1A, ~70% CTCF protein overexpression 
was, not surprisingly, associated with a 16.11-fold CTCF mRNA 
upregulation (Table 1). In contrast, ~90% CTCF protein knockdown 
seen in Figure 1B was associated with only a 4.32 fold change in CTCF 
mRNA (Table 1). The latter result however is not without precedent. 
Using single molecule fluorescence in situ hybridization (smFISH) and 
RNA sequencing (RNA-seq), Taniguchi, et al. [27] showed an almost 
complete lack of correlation between mRNA and protein expression 
levels in their experiments on single cell protein concentrations. They 
suggested that this was due to the different life spans of mRNA and 
protein as the former is very readily broken down while proteins 
accumulated from cycle to cycle. At any given time point therefore the 
mRNA levels could appear significantly lower than the corresponding 
proteins translated from them. 
This paper is probably the first to investigate a possible direct 
regulatory effect of CTCF gene expression change on ERα gene 
expression. Despite the previously described mutual interactions 
between CTCF and ERα, it is interesting, based on the results in this 
paper, that CTCF did not directly regulate ERα mRNA activity in 
the ER-positive MCF7 breast cancer cell line. It is possible that the 
previously mentioned interactions (see introduction) between CTCF 
and ERα could be limited in their application. For instance, the 
report of Ross-Ines was based on bioinformatics and may not reflect 
biologically significant endogenous interaction. Also the reported co-
recruitment of HDAC by CTCF and ERα was found after HDAC was 
overexpressed in the cell. This interaction could also be nonbiological 
as the HDAC protein expression would be grossly exaggerated in the 
cell. Moreover, the latter authors did not examine the opposite effect 
(HDAC1 knockdown) to determine whether the converse was true for 
the interaction they found. Taken together, it is possible to speculate 
that CTCF/ERα interaction could be an indirect effect mediated via 
protein partners or it might be that one protein initiates the event 
that leads to the recruitment of the other in an upstream/downstream 
interaction. The exact nature of the CTCF/ERα relationship obviously 
needs further enquiry.
Conclusions
We investigated the possibility of a direct regulatory relationship by 
CTCF on ERα expression at both the protein and mRNA level in the ER+ 
MCF7 breast cancer cell line. We found that ERα protein expression was 
not detectable by western blotting after MCF7 cell transfection and that 
variation in CTCF gene expression did not influence the expression of 
ERα mRNA. We speculate that the interaction between CTCF and ERα 
could be indirect, facilitated by protein partners.
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